FrancophonIA/ELRC3.0 huggingface dataset:
English: Rebif 8.8 micrograms solution for injection in pre-filled pen interferon beta-1a
Estonian: Rebif 8,8 mikrogrammi süstelahus pen-süstlis beeta-1a-interferoon
English: EU/1/98/063/004 1 pre-filled syringe EU/1/98/063/005 3 pre-filled syringes EU/1/98/063/006 12 pre-filled syringes EU/1/98/063/021 36 pre-filled syringes
Estonian: EU/1/98/063/004 1 süstel EU/1/98/063/005 3 süstlit EU/1/98/063/006 12 süstlit EU/1/98/063/021 36 süstlit
English: Each pre-filled pen contains 8.8 micrograms (2.4 MIU*) of interferon beta-1a** in 0.2 mL solution.
Estonian: Üks pen-süstel sisaldab 8,8 mikrogrammi (2,4 MRÜ*) beeta-1a-interferooni** 0,2 ml lahuses.
English: This medicinal product contains 2.5 mg benzyl alcohol per dose.
Estonian: Ravim sisaldab 2,5 mg bensüülalkoholi annuse kohta.
English: • or if you have any history of epileptic seizures, so that he/she can closely monitor your treatment and any worsening of these conditions.
Estonian: Siis oskab teie arst põhjalikumalt jälgida teie ravi kulgu ning iga võimalikku haiguse ägenemist.
English: Rebif 44 micrograms/0.5 mL solution for injection in cartridge interferon beta-1a
Estonian: Rebif 44 mikrogrammi/0,5 ml süstelahus kolbampullis beeta-1a-interferoon
English: EU/1/98/063/001 1 pre-filled syringe EU/1/98/063/002 3 pre-filled syringes EU/1/98/063/003 12 pre-filled syringes EU/1/98/063/020 36 pre-filled syringes
Estonian: EU/1/98/063/001 1 süstel EU/1/98/063/002 3 süstlit EU/1/98/063/003 12 süstlit EU/1/98/063/020 36 süstlit
English: Each pre-filled pen contains 44 micrograms (12 MIU*) of interferon beta-1a** in 0.5 mL solution.
Estonian: Üks pen-süstl sisaldab 44 mikrogrammi (12 MRÜ*) beeta-1a-interferooni** 0,5 ml lahuses.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Rebif 22 micrograms solution for injection interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Rebif 22 mikrogrammi süstelahus beeta-1a-interferoon
English: Hepatic dysfunction
Estonian: Kilpnäärmefunktsiooni häired
English: The pre-filled pen is ready for use and contains 0.2 mL of solution.
Estonian: Pen-süstel on kasutamiseks valmis ning sisaldab 0,2 ml süstelahust.
English: Other forms of multiple sclerosis
Estonian: Sclerosis multiplex'i muud vormid
English: NAME OF THE MEDICINAL PRODUCT Rebif 44 micrograms/0.5 mL solution for injection in cartridge interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS Rebif 44 mikrogrammi/0,5 ml süstelahus kolbampullis beeta-1a-interferoon
English: 12 pre-filled syringes.
Estonian: 12 süstlit.
English: This medicinal product contains 1.0 mg benzyl alcohol per dose of 0.2 mL and 2.5 mg benzyl alcohol per dose of 0.5 mL.
Estonian: Ravim sisaldab 1,0 mg bensüülalkoholi 0,2 ml annuse kohta ja 2,5 mg bensüülalkoholi 0,5 ml annuse kohta.
English: Rebif 22 micrograms/0.5 mL solution for injection in cartridge interferon beta-1a
Estonian: Rebif 22 mikrogrammi/0,5 ml süstelahus kolbampullis beeta-1a-interferoon
English: NAME OF THE MEDICINAL PRODUCT Rebif 44 micrograms solution for injection in pre-filled syringe
Estonian: RAVIMPREPARAADI NIMETUS Rebif 44 mikrogrammi süstelahus süstlis
English: Events were reported at various time points during treatment and may occur several weeks to several years after starting treatment with interferon beta.
Estonian: Juhtudest on teatatud ravi erinevatel perioodidel ja trombootiline mikroangiopaatia võib tekkida mõne nädala või mitme aastat pärast beeta-interferoonravi alustamist.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Rebif 44 micrograms solution for injection interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Rebif 44 mikrogrammi süstelahus beeta-1a-interferoon
English: After receiving adequate training, you, a family member, friend or carer can use RebiDose to administer the medicine at home.
Estonian: Pärast piisavate juhiste saamist võite te ise, teie perekonnaliige, teie sõber või hooldaja kasutada ravimi manustamiseks kodus RebiDose'i.
English: Rebif 8.8 micrograms/0.1 mL solution for injection in cartridge Rebif 22 micrograms/0.25 mL solution for injection in cartridge interferon beta-1a Initiation pack
Estonian: Rebif 8,8 mikrogrammi/0,1 ml süstelahus kolbampullis Rebif 22 mikrogrammi/0,25 ml süstelahus kolbampullis beeta-1a-interferoon Alustuspakend
English: Dyspnoea*
Estonian: krambid*
English: NAME OF THE MEDICINAL PRODUCT Rebif 44 micrograms solution for injection in pre-filled pen
Estonian: RAVIMPREPARAADI NIMETUS Rebif 44 mikrogrammi süstelahus pen-süstlis
English: Seizure disorders
Estonian: Süstekoha nekroos
English: During week three and four: 0.25 mL, which corresponds to the dose of 22 micrograms
Estonian: • Veenduge enne süstimist, et seadme annuseaknas valitud annus on: esimesel ja teisel nädalal: 0,1 ml, mis vastab 8,8-mikrogrammisele annusele; kolmandal ja neljandal nädalal: 0,25 ml, mis vastab 22-mikrogrammisele annusele.
English: NAME OF THE MEDICINAL PRODUCT Rebif 8.8 micrograms/0.1 mL solution for injection in cartridge Rebif 22 micrograms/0.25 mL solution for injection in cartridge interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS Rebif 8,8 mikrogrammi/0,1 ml süstelahus kolbampullis Rebif 22 mikrogrammi/0,25 ml süstelahus kolbampullis beeta-1a-interferoon
English: Pack size of 2 cartridges.
Estonian: Pakendis on 2 kolbampulli.
English: The solution for injection in a pre-filled syringe is ready for use.
Estonian: Süstelahus väljastatakse kasutamiseks valmis süstlites.
English: NAME OF THE MEDICINAL PRODUCT Rebif 22 micrograms/0.5 mL solution for injection in cartridge interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS Rebif 22 mikrogrammi/0,5 ml süstelahus kolbampullis beeta-1a-interferoon
English: NAME OF THE MEDICINAL PRODUCT Rebif 22 micrograms solution for injection in pre-filled pen
Estonian: RAVIMPREPARAADI NIMETUS Rebif 22 mikrogrammi süstelahus pen-süstlis
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Rebif 8.8 mcg solution for injection interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Rebif 8,8 μg süstelahus beeta-1a-interferoon
English: The pre-filled syringe is ready for use and contains 0.5 mL of solution.
Estonian: Süstel on kasutamiseks valmis ning sisaldab 0,5 ml süstelahust.
English: • Gently massage the injection site with a dry cotton ball or gauze.
Estonian: • Masseerige õrnalt süstekohta vati- või marlitupsuga.
English: The pre-filled pen is ready for use and contains 0.5 mL of solution.
Estonian: Pen-süstel on kasutamiseks valmis ning sisaldab 0,5 ml süstelahust.
English: Rebif 22 micrograms solution for injection interferon beta-1a
Estonian: Rebif 22 mikrogrammi süstelahus süstlis beeta-1a-interferoon
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/063/009
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/98/063/009
English: NAME OF THE MEDICINAL PRODUCT Rebif 44 micrograms solution for injection in pre-filled syringe interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS Rebif 44 mikrogrammi süstelahus süstlis beeta-1a-interferoon
English: Store the pre-filled pen in the original package in order to protect from light.
Estonian: Hoida pen-süstel originaalpakendis valguse eest kaitstult.
English: After receiving adequate training, you, a family member, friend or carer can use Rebif cartridges with your device to administer the medicine at home.
Estonian: Pärast piisavate juhiste saamist võite te ise, teie perekonnaliige või teie sõber või hooldaja kasutada ravimi manustamiseks kodus Rebif'i kolbampulle koos teie seadmega.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/063/007
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/98/063/007
English: NAME OF THE MEDICINAL PRODUCT Rebif 44 micrograms solution for injection in pre-filled pen interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS Rebif 44 mikrogrammi süstelahus pen-süstlis beeta-1a-interferoon
English: NAME OF THE MEDICINAL PRODUCT Rebif 8.8 micrograms solution for injection in pre-filled syringe Rebif 22 micrograms solution for injection in pre-filled syringe interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS Rebif 8,8 mikrogrammi süstelahus süstlis Rebif 22 mikrogrammi süstelahus süstlis beeta-1a-interferoon
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/063/017
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/98/063/017
English: NAME OF THE MEDICINAL PRODUCT Rebif 22 micrograms solution for injection in pre-filled pen interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS Rebif 22 mikrogrammi süstelahus pen-süstlis beeta-1a-interferoon
English: Composition: Each pre-filled pen contains 44 micrograms (12 MIU) of interferon beta-1a in 0.5 mL solution.
Estonian: TOIMEAINE(TE) SISALDUS Koostis: üks pen-süstel sisaldab 44 mikrogrammi (12 MRÜ) beeta-1a-interferooni 0,5 ml lahuses.
English: 1 pre-filled pen.
Estonian: Süstelahus pen-süstlis.
English: NAME OF THE MEDICINAL PRODUCT Rebif 22 micrograms solution for injection in pre-filled syringe interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS Rebif 22 mikrogrammi süstelahus süstlis beeta-1a-interferoon
English: Rebif 44 micrograms solution for injection in pre-filled syringe interferon beta-1a
Estonian: Rebif 44 mikrogrammi süstelahus süstlis beeta-1a-interferoon
English: Each pre-filled pen contains 22 micrograms (6 MIU*) of interferon beta-1a** in 0.5 mL solution.
Estonian: Üks pen-süstel sisaldab 22 mikrogrammi (6 MRÜ*) beeta-1a-interferooni** 0,5 ml lahuses.
English: Rebif 8.8 micrograms solution for injection interferon beta-1a
Estonian: (ÜLEMINE KIHT) Rebif 8,8 mikrogrammi süstelahus beeta-1a-interferoon Subkutaanne
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/063/008
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/98/063/008
English: Patients with multiple sclerosis
Estonian: Ägenemistega sclerosis multiplex
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/063/011
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/98/063/011
English: If you have any further questions, please ask your doctor, nurse or pharmacist.
Estonian: Kui teil on lisaküsimusi, pidage nõu oma arsti, meditsiiniõe või apteekriga.
English: NAME OF THE MEDICINAL PRODUCT Rebif 22 micrograms solution for injection in pre-filled syringe
Estonian: RAVIMPREPARAADI NIMETUS Rebif 22 mikrogrammi süstelahus süstlis
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/063/009 4 cartridges EU/1/98/063/019 12 cartridges
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/98/063/009 4 kolbampulli.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/063/014
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/98/063/014
English: If the patient population was divided into 2 subgroups (those with and those without relapses in the 2-year period prior to study entry), there was no effect on disability in patients without relapses, but in patients with relapses, the proportion with progression in disability at the end of the study was reduced from 70% (placebo) to 57% (Rebif 22 micrograms and 44 micrograms combined).
Estonian: Kui uuritud patsiendid jaotati kahte alarühma (need, kellel 2-aastase perioodi kestel enne uuringusse arvamist oli esinenud ägenemisi ning need, kellel uuringueelse 2 aasta jooksul ägenemisi ei olnud), täheldati, et ravimil puudus toime puude süvenemisele nendel patsientidel, kellel enne uuringut haiguse ägenemisi ei olnud.
English: After receiving adequate training, you, a family member, friend or carer can use Rebif syringes to administer the medicine at home.
Estonian: Pärast piisavate juhiste saamist võite te ise, teie perekonnaliige, teie sõber või hooldaja kasutada ravimi manustamiseks kodus Rebif'i süstleid.
English: Rebif 8.8 micrograms solution for injection in pre-filled pen Rebif 22 micrograms solution for injection in pre-filled pen interferon beta-1a Initiation pack
Estonian: Rebif 8,8 mikrogrammi süstelahus pen-süstlis Rebif 22 mikrogrammi süstelahus pen-süstlis beeta-1a-interferoon Alustuspakend
English: • Remove RebiDose from the injection site.
Estonian: • Eemaldage RebiDose süstekohalt.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Rebif 44 mcg solution for injection interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Rebif 44 μg süstelahus beeta-1a-interferoon
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Rebif 22 mcg solution for injection interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Rebif 22 μg süstelahus beeta-1a-interferoon
English: NAME OF THE MEDICINAL PRODUCT Rebif 8.8 micrograms solution for injection in pre-filled pen Rebif 22 micrograms solution for injection in pre-filled pen interferon beta-1a
Estonian: RAVIMPREPARAADI NIMETUS Rebif 8,8 mikrogrammi süstelahus pen-süstlis Rebif 22 mikrogrammi süstelahus pen-süstlis beeta-1a-interferoon
English: Rebif 44 micrograms solution for injection in pre-filled pen interferon beta-1a
Estonian: Rebif 44 mikrogrammi süstelahus pen-süstlis beeta-1a-interferoon
English: Composition: Each pre-filled pen contains 22 micrograms (6 MIU) of interferon beta-1a in 0.5 mL solution.
Estonian: TOIMEAINE(TE) SISALDUS Koostis: üks pen-süstel sisaldab 22 mikrogrammi (6 MRÜ) beeta-1a-interferooni 0,5 ml lahuses.
English: Rebif 8.8 micrograms solution for injection in pre-filled syringe Rebif 22 micrograms solution for injection in pre-filled syringe interferon beta-1a Initiation pack
Estonian: Rebif 8,8 mikrogrammi süstelahus süstlis Rebif 22 mikrogrammi süstelahus süstlis beeta-1a-interferoon Alustuspakend
English: Rebif 22 micrograms solution for injection in pre-filled pen interferon beta-1a
Estonian: Rebif 22 mikrogrammi süstelahus pen-süstlis beeta-1a-interferoon
English: Thyroid disorders
Estonian: Kilpnäärme funktsiooni häired
English: NAME OF THE MEDICINAL PRODUCT Rebif 8.8 micrograms solution for injection in pre-filled syringe Rebif 22 micrograms solution for injection in pre-filled syringe
Estonian: RAVIMPREPARAADI NIMETUS Rebif 8,8 mikrogrammi süstelahus süstlis Rebif 22 mikrogrammi süstelahus süstlis
English: Uncommon:
Estonian: Esinemissagedus teadmata:
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/063/010
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/98/063/010
English: Laboratory abnormalities are associated with the use of interferons.
Estonian: Seoses interferoonide kasutamisega on esinenud muutusi laboratoorsetes analüüsides.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/063/008 4 cartridges EU/1/98/063/018 12 cartridges
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/98/063/008 4 kolbampulli.
English: NAME OF THE MEDICINAL PRODUCT Rebif 8.8 micrograms solution for injection in pre-filled pen Rebif 22 micrograms solution for injection in pre-filled pen
Estonian: RAVIMPREPARAADI NIMETUS Rebif 8,8 mikrogrammi süstelahus pen-süstlis Rebif 22 mikrogrammi süstelahus pen-süstlis
English: •Before treatment with Rebif, read carefully and follow the advice given under “How to use Rebif” in order to minimise the risk of injection site necrosis (skin breakdown and tissue destruction) that has been reported in patients treated with Rebif.
Estonian: • Enne ravi Rebif'iga lugege hoolikalt läbi ning järgige nõuandeid, mis on toodud alalõigus “Kuidas Rebif'i kasutada”.
English: Solution for injection in pre-filled syringe.
Estonian: ravimi poolt esilekutsutud erütematoosne luupus*
English: 2 cartridges
Estonian: 2 kolbampulli.
English: The solution for injection in a pre-filled pen is ready for use.
Estonian: Süstelahus väljastatakse kasutamiseks valmis pen-süstlites.
English: Batch
Estonian: Tootja
English: Portugal
Estonian: European Medicines Agency
English: What TESLASCAN is and what it is used for.
Estonian: Milleks TESLASCANi kasutatakse?
English: EXP
Estonian: ©EMEA 2007
English: It should be administered as an intravenous infusion at the rate of 2-3 ml/min for liver imaging and at a rate of 4-6 ml/min for imaging of the pancreas.
Estonian: Infusioonikiirus on maksauuringute korral 2-3 ml/min ja kõhunäärmeuuringute korral 4-6 ml/min.
English: Near maximal enhancement of the normal liver and pancreas parenchyma is generally observed 15-20 minutes from the start of administration and lasts for approximately 4 hours.
Estonian: Kujutise kontrastsuse paranemine algab 15-20 minuti möödumisel infusiooni algusest ja püsib ligikaudu 4 tundi.
English: This medicine is for diagnostic use only.
Estonian: Seda ravimit saab üksnes retsepti alusel.
English: PACKAGE LEAFLET: INFORMATION FOR THE USER
Estonian: EUROOPA AVALIK HINDAMISARUANNE TESLASCAN Kokkuvõte üldsusele
English: If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell the radiologist/radiographer or your doctor or pharmacist.
Estonian: Kui vajate oma haigusseisundi või ravi osas asjakohast lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või võtke ühendust oma arsti või apteekriga.
English: Suomi/Finland
Estonian: EMEA/H/C/137
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 22.05.1997
Estonian: Müügiluba pikendati 22. mail 2002 ja 22. mail 2007.
English: Those most commonly reported were: feeling of warmth/flushing, headache and nausea.
Estonian: TESLASCANi kõige sagedamad kõrvalnähud (mida on esinenud ühel kuni kümnel patsiendil sajast) on peavalu, iiveldus, õhetus ja kuumatunne.
English: United Kingdom GE Healthcare Limited Amersham Place Little Chalfont HP7 9NA - UK Tel: + 44 (0) 1 494 54 4000
Estonian: 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
English: What TESLASCAN contains - The active substance is mangafodipir trisodium.
Estonian: TESLASCAN on infusioonilahus (veeni tilgutamiseks), mille toimeaine on mangafodipiirtrinaatrium.
English: For a full list of excipients, see section 6.1.
Estonian: TESLASCANi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Contrast medium for diagnostic Magnetic Resonance Imaging (MRI) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas.
Estonian: TESLASCANi kasutatakse patsientidel, kellele tehakse magnetresonantstomograafia (MRI) maksa koekahjustuste avastamiseks, mis võivad olla põhjustatud maksavähist või muudest kehaosadest maksa levinud vähist.
English: This corresponds to a dose of 35 ml for a 70 kg person.
Estonian: TESLASCANi manustatakse ühekordse intravenoosse infusioonina annuses 0,5 ml kehakaalu kilogrammi kohta.
English: TESLASCAN is for use in patients over the age of 18 years.
Estonian: Kokku leiti 33%-l patsientidest pärast TESLASCANi manustamist uuringul kahjustusi rohkem ja 20%-l patsientidest vähem.
English: For any information about this medicine, please contact the local representative of the Marketing
Estonian: Kui soovite lisateavet inimtervishoius kasutatavate ravimite komitee soovituste aluse kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa avaliku hindamisaruande osa).
English: TESLASCAN is used in magnetic resonance imaging (MRI) to detect certain lesions in the liver and
Estonian: TESLASCANi võib kasutada magnetresonantstomograafias ka kõhunäärme kahjustuste uurimiseks.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Estonian: Komitee soovitas anda TESLASCANile müügiloa.
English: TESLASCAN is a paramagnetic contrast medium used in connection with Magnetic Resonance Imaging (MRI), to improve the diagnostic information.
Estonian: Mangaani kasutatakse kontrastainena, et saada magnetresonantstomograafias paremaid kujutisi.
English: Satis Lda.
Estonian: Mis on TESLASCAN?
English: Care should be exercised in patients with severe cardiac disease and in patients with injuries of the blood brain barrier and severe cerebral disease.
Estonian: TESLASCANi ei tohi kasutada raseduse ega imetamise ajal, samuti feokromotsütoomiga (neerupealise teatud kasvaja) patsiendid ega raskete maksa- või neeruprobleemidega patsiendid.
English: There are limited data available on the use of Teslascan in children.
Estonian: Milles seisneb uuringute põhjal TESLASCANi kasulikkus?
English: Tel: + 43 1 972 72-0
Estonian: Kokkuvõtte viimane uuendus: 04-2007.
English: Mangafodipir is a chelate containing the metal manganese - which has paramagnetic properties and is responsible for the contrast enhancement effect in MRI - and the ligand fodipir (dipyridoxyl diphosphate).
Estonian: TESLASCANi toimeaine mangafodipiir sisaldab mangaani, mis on metallide hulka kuuluv keemiline element.
English: FURTHER INFORMATION
Estonian: Muu teave TESLASCANi kohta:
English: Rarely, hypersensitivity reactions (urticaria and other possible allergic phenomena) or anaphylactoid reactions may occur.
Estonian: TESLASCANi ei tohi kasutada patsiendid, kes võivad olla ülitundlikud (allergilised) mangafodipiirtrinaatriumi või ravimi mis tahes muu koostisaine suhtes.
English: Serious adverse events have not been reported in healthy subjects with dosages up to 5 times the normal clinical dose (maximum dose investigated).
Estonian: Kõhunäärmehaiguste uurimisel osales 292 patsienti, kellel võrreldi TESLASCANiga kontrasteeritud magnetresonantsuuringu efektiivsust spiraalse CT-ga (samuti kõhunäärmekahjustuste avastamise diagnostikameetod).
English: SPECIAL STORAGE CONDITIONS Keep the vial in the outer carton in order to protect from light.
Estonian: Magnetväli mõjutab kehas veemolekule ja tekitab raadiolainete kasutamisel signaali.
English: Lesion-related enhancement of certain types of lesions, such as liver metastases and hepatocellular carcinomas, may be detectable for up to 24 hours.
Estonian: Ravimi manustamisel mangaan vabaneb ning normaalsed maksa- ja kõhunäärmekoed seovad seda efektiivsemini kui vähirakud.
English: Slovenská republika GE Healthcare SCE Handels GmbH Branch Office Slovakia Floriánske nám.
Estonian: Euroopa Komisjon väljastas TESLASCANi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele GE Healthcare AS 22. mail 1997.
English: Treatment will be supportive to relieve the symptoms.
Estonian: Mangaan seondub veemolekulidega, nii et need annavad tugevama signaali, mis aitab saada kontrastsema pildi.
English: The degree of excretion into human breast milk is not known.
Estonian: See võimaldab eristada normaalset kude ebanormaalsest.
English: Mangafodipir trisodium
Estonian: Kuidas TESLASCAN toimib?
English: No studies on the effects on the ability to drive and use machines have been performed.
Estonian: Selles selgitatakse, kuidas inimtervishoius kasutatavate ravimite komitee hindas teostatud uuringuid, et koostada soovitused ravimi kasutamise kohta.
English: Mangafodipir is teratogenic in rats; it causes increased foetal skeletal abnormalities when given daily by intravenous injection to female rats at dosages slightly greater than clinical dosages.
Estonian: Inimtervishoius kasutatavate ravimite komitee jõudis otsusele, et TESLASCANi kasulikkus kontrastainena diagnostilises magnetresonantstomograafias maksakahjustuste avastamiseks, mis võivad olla põhjustatud metastaasidega haigusest või hepatotsellulaarsest kartsinoomist, ning lisaks magnetresonantstomograafiale koldeliste kõhunäärmekahjustuste uurimisel on suurem kui sellega kaasnevad riskid.
English: These measures will help protect environment.
Estonian: Need meetmed aitavad kaitsta keskkonda.
English: Therefore careful monitoring will be performed.
Estonian: Seetõttu teostatakse hoolikat järelvalvet.
English: These risks are assessed in the corresponding national procedures.
Estonian: Neid riske hinnatakse vastavates riiklikes protseduurides.
English: 9 to < 16 16 to 23 > 23 to 34
Estonian: 9 kuni < 16 16 kuni 23 23 kuni 34
English: Ask your pharmacist how to throw away medicine you no longer use.
Estonian: Küsige oma apteekrilt, kuidas visata ära ravimeid, mida te enam ei kasuta.
English: The long-term outcomes confirmed that the efficacy was maintained without unexpected effects.
Estonian: Pikaajalised tulemused kinnitasid, et efektiivsus säilis ootamatute mõjudeta.
English: By example:
Estonian: Näiteks:
English: Therefore special care is recommended when combining these two compounds.
Estonian: Seetõttu on soovitatav eriline ettevaatus nende kahe aine kombineerimisel.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/03/254/002
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/03/254/002